Clinical Trial Update: Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules [Phase 4]

View source ↗

Summary

Phase 4 study evaluating long-term immunogenicity up to 10 years after first booster in adults across three primary vaccination schedules for Tick Borne Encepha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tick-borne Encephalitis

Drugs mentioned

• Tick-borne encephalitis vaccine (Tick-borne encephalitis vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Tick Borne Encephalitis, Virus Diseases | Phase 4 | Status: COMPLETED | Results posted: 2018-08-31